Groups representing health centers, HIV/AIDS clinics, and hospitals asked federal appeals courts in Philadelphia and Washington, D.C., this week to hold that drug manufacturers must give covered entities 340B discounts on drugs when entities use contract pharmacies to
…
Drug manufacturers’ conditions on 340B pricing when covered entities use contract pharmacies violate federal law and ultimately diminish states’ public health efforts, 25 states told two federal appeals courts yesterday.
Twenty-five states are backing the federal government in litigation before two federal appeals courts over drug manufacturers’ denials of 340B pricing when covered entities use contract pharmacies.
Letting drug manufacturers put conditions on 340B drug discounts “would be akin to letting the fox guard the henhouse,” the U.S. Justice Department (DOJ) told federal appeals courts in Philadelphia and Washington, D.C., last night in a pair
…
A federal district judge on Tuesday let Arkansas’ state health center association and a critical access hospital in the state have a role in the drug industry’s lawsuit challenging the state’s one-of-a-kind law protecting 340B contract pharmacy arrangements.
…
California health centers asked a federal district judge in late April to deny the U.S. Centers for Medicare & Medicaid Services (CMS) motion to dismiss the health centers’ claims against CMS arising over the state’s transfer of Medicaid
…
A federal appeals court in Philadelphia, as expected, has decided to consider and rule on AstraZeneca’s 340B contract pharmacy lawsuit in tandem with Sanofi and Novo Nordisk’s 340B contract pharmacy cases.
A federal appeals court in Chicago is satisfied with the final judgement it ordered a lower court to issue in Lilly’s 340B contract pharmacy lawsuit, clearing the way the lawsuit’s next stage to get rolling.
A federal district judge in Indianapolis last week responded to a higher court’s directive and entered an amended partial final judgement in drug manufacturer Lilly’s 340B contract pharmacy lawsuit.
The federal government on Monday accused a Tennessee health system of unlawfully paying a Memphis-area private oncology practice for patient referrals, letting the system “recoup a staggering discount in costs” through the 340B program.
